PURPOSE: This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens. METHODS: Twenty-six patients of European or South Asian ethnicity, who had suffered liver injury during treatment with isoniazid-containing drug regimens and 101 ethnically matched controls were genotyped for the NAT2*5, NAT2*6, and NAT2*7 alleles. Genotyping for additional polymorphisms in the NAT gene region was also performed on 20 of the 26 cases. NAT2 genotype frequency between cases and controls was compared. RESULTS: NAT2 genotypes predicting a slow acetylator phenotype were found to be associated with an increased risk of isoniazid-related liver injury (odds ratio (OR) = 4.25 (95% confidence interval (CI), 1.36-13.22); p = 0.012) with 85% of the cases being slow acetylators compared with 56% of the controls. There was no evidence for an increased risk for the slow acetylator genotype in patients with the most severe cases of liver injury, who underwent liver transplantation. CONCLUSIONS: The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury. However, the overall effect size is modest and generally in line with effects described previously for this genotype in milder drug-induced liver injury. Additional genetic risk factors may also contribute.
PURPOSE: This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens. METHODS: Twenty-six patients of European or South Asian ethnicity, who had suffered liver injury during treatment with isoniazid-containing drug regimens and 101 ethnically matched controls were genotyped for the NAT2*5, NAT2*6, and NAT2*7 alleles. Genotyping for additional polymorphisms in the NAT gene region was also performed on 20 of the 26 cases. NAT2 genotype frequency between cases and controls was compared. RESULTS: NAT2 genotypes predicting a slow acetylator phenotype were found to be associated with an increased risk of isoniazid-related liver injury (odds ratio (OR) = 4.25 (95% confidence interval (CI), 1.36-13.22); p = 0.012) with 85% of the cases being slow acetylators compared with 56% of the controls. There was no evidence for an increased risk for the slow acetylator genotype in patients with the most severe cases of liver injury, who underwent liver transplantation. CONCLUSIONS: The NAT2 slow acetylator genotype appears to be a significant risk factor for moderate and severe drug- induced liver injury. However, the overall effect size is modest and generally in line with effects described previously for this genotype in milder drug-induced liver injury. Additional genetic risk factors may also contribute.
Authors: L Ben Mahmoud; H Ghozzi; A Kamoun; A Hakim; H Hachicha; S Hammami; Z Sahnoun; N Zalila; H Makni; K Zeghal Journal: Pathol Biol (Paris) Date: 2012-10
Authors: Guruprasad P Aithal; Lesley Ramsay; Ann K Daly; Nhareet Sonchit; Julian B S Leathart; Graeme Alexander; J Gerald Kenna; John Caldwell; Christopher P Day Journal: Hepatology Date: 2004-05 Impact factor: 17.425
Authors: Julián G Chamorro; Jorge P Castagnino; Rosa M Musella; Mabel Nogueras; Federico M Aranda; Ana Frías; Mabel Visca; Omar Aidar; Silvia Perés; Gabriela F de Larrañaga Journal: J Gastroenterol Hepatol Date: 2013-02 Impact factor: 4.029
Authors: Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma Journal: Biochem Pharmacol Date: 2017-09-06 Impact factor: 5.858
Authors: Henrik Cordes; Christoph Thiel; Hélène E Aschmann; Vanessa Baier; Lars M Blank; Lars Kuepfer Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191